Fagron solidifies its leadership position with the acquisition of Guinama in Spain

Regulated information

Nazareth (Belgium)/Rotterdam (The Netherlands), 4 Feb 2025 – 7AM CET

Fagron solidifies its leadership position with the acquisition of Guinama in Spain

Fagron, the leading global player in pharmaceutical compounding is pleased to announce the acquisition of Guinama in Spain. This acquisition underscores Fagron’s commitment to expanding across our key markets whilst adhering to our disciplined acquisition strategy.

Guinama, based in Valencia, Spain, specializes in repackaging and distribution of active pharmaceutical ingredients and excipients to pharmacies, hospitals and industries. It is known for its excellent customer service and strong competitive position, especially for high-volume and fast-moving products. Guinama strengthens Fagron’s market positioning in the Iberian pharmaceutical compounding market, further solidifying its leading role within the sector and country.

The enterprise value of the acquisition is c.€22m and the acquisition will close on signing. Guinama generates low double-digit (€m) of annual revenue and has an EBITDA margin slightly above Fagron’s existing group margin.

Rafael Padilla, CEO of Fagron commented: “The acquisition of Guinama aligns perfectly with our disciplined, strategic approach to growth. This acquisition solidifies our repackaging and distribution activities in EMEA, whilst strengthening our market leadership position in Iberia. Key synergies of this integration will come from optimized sourcing, streamlined back-office operations, centralized warehousing, and a shift of production to Poland.”

Financial calendar 2025

20 February                  Full year results 2024

10 April                        Trading update first quarter 2025

12 May                        Annual shareholders meeting

31 July                        Half year results 2025

9 October                    Trading update third quarter 2025



Results and trading updates are published at 7.00 AM CET

Further information

Karin de Jong

Chief Financial Officer

About Fagron

Fagron is a leading global company active in pharmaceutical compounding, focusing on delivering personalized medicine to hospitals, pharmacies, clinics and patients in more than 30 countries around the world.

Belgian company Fagron NV has its registered office in Nazareth and is listed on Euronext Brussels and Euronext Amsterdam under the ticker symbol ‘FAGR’. Fagron’s operational activities are managed by the Dutch company Fagron BV, which is headquartered in Rotterdam.

Important information regarding forward-looking statements

Certain statements in this press release may be deemed to be forward-looking. Such forward-looking statements are based on current expectations and are influenced by various risks and uncertainties. Consequently, Fagron cannot provide any guarantee that such forward-looking statements will, in fact, materialize and cannot accept any obligation to update or revise any forward-looking statement as a result of new information, future events or for any other reason.

In the event of differences between the English translation and the Dutch original of this press release, the latter prevails.

Attachment